Nicox (FRA:NXOA) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NXOA Nicox SA FRA:NXOA
37 GF Score
Price €0.31
GF Value €0.61
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Nicox FFO?

FFO (Funds from operations) only applies to REITs.

FRA:NXOA
37GF Score
Nicox SA FRA:NXOA
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Nicox (FRA:NXOA) Overvalued in 2026?

Based on GuruFocus' analysis, Nicox stock appears to be undervalued. The current stock price of €0.31 is trading 49.7% below its estimated GF Value™ of €0.61. GuruFocus considers Nicox to be Possible Value Trap.

Key valuation signals for FRA:NXOA:

  • FFO:
  • GF Value™: €0.61 vs. price of €0.31 (49.7% below fair value)
  • GF Score™: 37/100 with 2 warning signs

No single metric tells the full story. See the FRA:NXOA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nicox Business Description

Address Rue Evariste Galois, Emerald Square, Batiment C, Sundesk Sophia Antipolis, Biot, FRA, 06410
Nicox SA is an international ophthalmology company developing solutions to help preserve vision and improve ocular health. It is developing a portfolio of treatments targeting glaucoma, diseases of the anterior segment and retinal diseases. A drug candidate (NCX 470) in phase 3 clinical development designed to reduce intraocular pressure ("IOP") in patients with open-angle glaucoma or ocular hypertension. A drug candidate (NCX 1728) in preclinical development for retinal diseases and glaucoma, derived from Nicox's proprietary nitric oxide (NO)-donating research platform. Its products are ZERVIATE, VYZULTA, Naproxcinod, etc.
37GF Score

Get the complete analysis for FRA:NXOA

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.31
Price
€0.61
GF Value